This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Schering Corporation. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Innovations of John A. Howe in Adenovirus Production
Introduction
John A. Howe is a notable inventor based in Green Brook, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the production of adenoviruses. His work has implications for gene therapy and vaccine development.
Latest Patents
John A. Howe holds a patent for "Cell lines for production of replication-defective adenovirus." This invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. Additionally, it includes cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B, and E2B polymerase functions. The invention features specific cell lines that enhance E1A function through the insertion of an E1A sequence with mutations in the 243R and 289R proteins, along with an E1B sequence comprising the E1B-55K gene. The production yields from the resulting producer cell lines, designated SL0003 and SL0006, were comparable to those obtained from 293 cells, without generating detectable recombinant replication competent adenovirus (RCA).
Career Highlights
John A. Howe is associated with Schering Corporation, where he has contributed to advancements in biotechnology. His work has been pivotal in enhancing the efficiency of adenovirus production, which is crucial for various medical applications.
Collaborations
Some of his notable coworkers include Ken N. Wills and Robert Orville Ralston, II. Their collaborative efforts have furthered research and development in the field of adenoviral vectors.
Conclusion
John A. Howe's innovations in adenovirus production represent a significant advancement in biotechnology. His contributions are essential for the ongoing development of gene therapies and vaccines.